Search Results 21-30 of 37524 for Two-phase

  1. Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk Myelodysplastic Syndromes - Mayo Clinic

    Phase 2, 80 new subjects will be randomized in a 1:1 ratio into 2 doses/schedules. Participation eligibility. Participant eligibility includes age, gender, type ...

  2. Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) - Mayo Clinic

    Study ACT16970 consists of 2 parts (A and B) as follows: Part A is a 24 week, double blind, placebo controlled part, preceded by a screening period of up to 4 ...

  3. A Phase 2/3 Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Subjects With Unresectable or Metastatic Melanoma - Mayo Clinic

    About this study. This is an adaptive clinical trial that includes a dose escalation phase followed by a randomized controlled Phase 3 trial.

  4. A Phase 2, Multicenter, Randomized Study of AP26113 - Mayo Clinic

    The purpose of this study is to evaluate the efficacy and safety of two different dosing regimens of AP26113 in patients with anaplastic lymphoma kinase (ALK)- ...

  5. Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients with ALS - Mayo Clinic

    Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients with ALS · More about research at Mayo Clinic.

  6. Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations - Mayo Clinic

    BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage ...

  7. Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in NMIBC - Mayo Clinic

    Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in NMIBC · Overview · Participation eligibility · Participating Mayo Clinic ...

  8. RESET-SLE: A Phase 1/​2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus - Mayo Clinic

    RESET-SLE: A Phase 1/​2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus · Overview.

  9. A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction - Mayo Clinic

    Clinical Trials · A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction · More about research at Mayo Clinic.

  10. Study Is To Assess The Safety And Tolerability Of VTx-002 In Participants With ALS - Mayo Clinic

    PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose ... Two escalating dose (low dose and high dose) cohorts are planned. The duration ...